Integrating Rapid Diabetes Screening Into a Latinx Focused Community-Based Low-Barrier COVID-19 Testing Program.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
02 05 2022
Historique:
entrez: 26 5 2022
pubmed: 27 5 2022
medline: 31 5 2022
Statut: epublish

Résumé

Community-based COVID-19 testing and vaccination programs play a crucial role in mitigating racial and ethnic disparities in COVID-19 service delivery. They also represent a platform that can be leveraged to expand access to testing for chronic diseases, including diabetes, that disproportionately affect the Latinx community and other marginalized communities. To evaluate outcomes associated with a diabetes testing strategy designed to reach low-income Latinx persons by leveraging COVID-19 testing infrastructure and community trust developed during the COVID-19 pandemic. This health care improvement study was conducted from August 1 to October 5, 2021, at an outdoor, community-based COVID-19 testing site at a transport hub in the Mission Neighborhood in San Francisco, California. Because the program was designed to expand access to diabetes screening to the local community, all individuals presenting for on-site testing were eligible. Data were analyzed in November 2021. Integration of rapid, point-of-care hemoglobin A1c screening as a testing option in an existing low-barrier COVID-19 testing program. Evaluation was guided by the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework and utilized programmatic data and structured surveys among clients and staff. Of 6631 individuals tested (median [IQR] age 39.3 [29.7-51.3] years; 3417 [52.3%] female, 4348 [65.6%] Latinx), 923 (13.9%) underwent hemoglobin A1c testing with or without COVID-19 testing and 5708 (86.1%) underwent COVID-19 testing only. Individuals tested for diabetes were more likely to be Latinx (763 of 923 individuals [82.7%] who underwent testing were Latinx vs 3585 of 5708 [62.8%] not undergoing testing), have an annual household income of less than $50 000 (450 individuals [81.2%] vs 2409 individuals [66.0%]), and not have health insurance (381 individuals [47.2%] vs 1858 individuals [39.9%]), and 206 (48.0%) had never tested for diabetes before. Overall, 313 (33.9%) and 113 (12.2%) individuals had prediabetes and diabetes, respectively; only 141 of 354 of these individuals (39.8%) had a primary care clinician whom they had seen in the prior 12 months, which was lower among Latinx individuals (113 of 307 individuals [36.8%] vs 28 of 47 [59.6%]). Acceptability of the rapid testing program was high-98% were satisfied with their visit and 96% said they would return for future services; key factors underpinning acceptability included friendly staff, efficiency, and a convenient location. In this health care improvement study conducted within an existing community-based COVID-19 testing program, integrating rapid testing for diabetes was feasible, reached low-income Latinx individuals, and identified many persons with prediabetes and diabetes, most of whom lacked access to services in formal health care settings. Leveraging pandemic-related public health responses represents an important opportunity for engaging socioeconomically disadvantaged populations into care for diabetes.

Identifiants

pubmed: 35616939
pii: 2792722
doi: 10.1001/jamanetworkopen.2022.14163
pmc: PMC9136625
doi:

Substances chimiques

Glycated Hemoglobin A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2214163

Références

J Diabetes Res. 2016;2016:2456518
pubmed: 26881242
Implement Sci. 2017 Aug 29;12(1):108
pubmed: 28851459
Health Promot Pract. 2006 Jan;7(1):26-33
pubmed: 16410418
Open Forum Infect Dis. 2021 Jan 20;8(2):ofab023
pubmed: 33623805
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Am J Kidney Dis. 2019 Jan;73(1):102-111
pubmed: 29661541
Front Public Health. 2019 Aug 21;7:215
pubmed: 31497586
PLoS One. 2020 Oct 9;15(10):e0239400
pubmed: 33035216
J Ambul Care Manage. 2010 Apr-Jun;33(2):155-62
pubmed: 20228639
Lancet Glob Health. 2021 Jun;9(6):e749-e750
pubmed: 33713634
Int J Pharm Pract. 2013 Dec;21(6):349-61
pubmed: 23683090
Diabetes Res Clin Pract. 2016 Oct;120:73-80
pubmed: 27522562
Am J Prev Med. 2004 May;26(4):271-5
pubmed: 15110052
Prev Chronic Dis. 2020 Jul 16;17:E65
pubmed: 32678059
Prev Chronic Dis. 2021 Oct 07;18:E91
pubmed: 34618667
Diabetes Care. 2003 Mar;26(3):668-70
pubmed: 12610019
JAMA Intern Med. 2020 Apr 1;180(4):596-597
pubmed: 31985740
Annu Rev Public Health. 2016;37:375-94
pubmed: 26789384
Can Pharm J (Ott). 2012 Jul;145(4):165-7
pubmed: 23509544
Health Info Libr J. 2014 Dec;31(4):254-73
pubmed: 25209260
J Immigr Minor Health. 2014 Aug;16(4):565-75
pubmed: 24363118
J Am Pharm Assoc (2003). 2006 May-Jun;46(3):370-7
pubmed: 16739759
Front Public Health. 2017 Jun 12;5:135
pubmed: 28660184
Ethn Dis. 2014 Spring;24(2):195-9
pubmed: 24804366
JAMA. 2021 Feb 23;325(8):719-720
pubmed: 33480972
Am J Public Health. 2021 Apr;111(4):658-662
pubmed: 33600248
J Racial Ethn Health Disparities. 2021 Oct 13;:
pubmed: 34647273
Prev Chronic Dis. 2020 Dec 10;17:E158
pubmed: 33301390
Health Serv Res Manag Epidemiol. 2018 Jan 21;5:2333392817752211
pubmed: 29383325
PLoS One. 2021 Sep 20;16(9):e0257111
pubmed: 34543291
J Natl Med Assoc. 2004 Oct;96(10):1325-31
pubmed: 15540883
Am J Ophthalmol. 2010 May;149(5):752-61.e1-3
pubmed: 20149342
Am J Med. 2011 Oct;124(10 Suppl):S2-9
pubmed: 21939795
PLoS One. 2020 Jun 5;15(6):e0233839
pubmed: 32502193
Front Public Health. 2020 May 12;8:134
pubmed: 32478025

Auteurs

Andrew D Kerkhoff (AD)

Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco.

Susana Rojas (S)

San Francisco Latino Task Force-Response to COVID-19, San Francisco, California.

Douglas Black (D)

Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco.

Salustiano Ribeiro (S)

Bay Area Phlebotomy and Laboratory Services, San Francisco, California.

Susy Rojas (S)

Unidos en Salud, San Francisco, California.

Rebecca Valencia (R)

Unidos en Salud, San Francisco, California.

Jonathan Lemus (J)

Unidos en Salud, San Francisco, California.

Joselin Payan (J)

Unidos en Salud, San Francisco, California.

John Schrom (J)

Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco.

Diane Jones (D)

Unidos en Salud, San Francisco, California.

Simone Manganelli (S)

Unidos en Salud, San Francisco, California.

Gabriel Chamie (G)

Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco.

Valerie Tulier-Laiwa (V)

San Francisco Latino Task Force-Response to COVID-19, San Francisco, California.

Maya Petersen (M)

Division of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley.

Diane Havlir (D)

Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco.

Carina Marquez (C)

Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH